Cancer Family
Malignant Digestive System Neoplasm
CI-CAN-00000229Explore in graph →
4,262 active trials43 approved drugs556 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000229Explore in graph →
Clinical trials
19,108 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2,001)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05024812 | Fruquintinib Combined With Toripalimab and SOX Regimen in the First-line Treatment of Advanced Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | unknown | Phase 1 / Phase 2 | 64 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT05493332 | HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC | unknown | Phase 2 | 93 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 |
| Aug 18, 2022 |
| clinicaltrials |
| NCT04699994 | Prospective Trial to Evaluate the Safety and Efficacy to Treat Esophageal Cancer Using 5-FU, Oxaliplatin, and Docetaxel | unknown | Phase 2 | 60 | Keio UniversityOTHER | 1 | Aug 17, 2022 | clinicaltrials |
| NCT04924179 | Tislelizumab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With Advanced CRC | unknown | Phase 2 | 25 | Huazhong University of Science and TechnologyOTHER | 1 | Aug 17, 2022 | clinicaltrials |
| NCT05170256 | Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients(HERES) | unknown | Phase 2 | 24 | Morten Mau-SørensenOTHER | 1 | Aug 12, 2022 | clinicaltrials |
| NCT05497739 | Intraperitoneal Chemotherapy Guided by the Detection of DNA in Peritoneal Lavage Fluid in Patients With Gastric Cancer | unknown | Phase 2 | 68 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT05181605 | Survival Analysis After Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer and Risk Factors | unknown | Phase 2 / Phase 3 | 116 | Instituto de investigación e innovación biomédica de CádizOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT05290116 | HAIC Combined With Tislelizumab and Apatinib for Unresectable Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 17 | Yunfei YuanOTHER | 1 | Aug 5, 2022 | clinicaltrials |
| NCT05487443 | The Efficacy of Chemotherapy Combined With Immunocheckpoint Inhibitors in Advanced Biliary Malignancies | unknown | Phase 2 / Phase 3 | 50 | First People's Hospital of HangzhouOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT05476380 | Neoadjuvant Therapy of Camrelizumab Combined With Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 39 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 27, 2022 | clinicaltrials |
| NCT04733963 | Fruquintinib Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer | unknown | Phase 2 | 112 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 26, 2022 | clinicaltrials |
| NCT05469061 | Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC | unknown | Phase 2 | 17 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 21, 2022 | clinicaltrials |
| NCT03946969 | Sintilimab in Combination With Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal Cancer | unknown | Phase 2 | 30 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 19, 2022 | clinicaltrials |
| NCT04362449 | Comparing the Current Hydration Regimen for the ABC02 Chemotherapy Regimen Versus a Shorter Hydration | unknown | Phase 2 | 30 | Imperial College Healthcare NHS TrustOTHER | 1 | Jul 15, 2022 | clinicaltrials |
| NCT05174156 | Study on the Biomarker of First-line Immunotherapy Combined With Chemotherapy in Advanced Esophageal Cancer | unknown | Phase 2 | 50 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Jul 14, 2022 | clinicaltrials |
| NCT05451719 | Fruquintinib Plus Capecitabine Versus Capecitabine as Maintenance Therapy for Metastatic Colorectal Cancer After First-line Chemotherapy | unknown | Phase 2 | 116 | Fudan UniversityOTHER | 0 | Jul 12, 2022 | clinicaltrials |
| NCT05449483 | Conversion of Tislelizumab Combined With Chemotherapy in Unresectable Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 40 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 8, 2022 | clinicaltrials |
| NCT05447715 | Fruquintinib Sequential BEV+FOLFIRI vs. BEV+FOLFIRI Sequential Fruquintinib in Metastatic Colorectal Cancer | unknown | Phase 2 | 134 | Weijian GuoOTHER | 1 | Jul 7, 2022 | clinicaltrials |
| NCT05439993 | Tepotinib Plus Paclitaxel in MET Amplified or MET Exon 14 Alterated Gastric and GEJ Carcinoma | unknown | Phase 1 / Phase 2 | 42 | Hallym University Medical CenterOTHER | 1 | Jul 5, 2022 | clinicaltrials |
| NCT05438108 | SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab in First-line Treatment of mCRC | unknown | Phase 2 | 30 | Huazhong University of Science and TechnologyOTHER | 1 | Jun 29, 2022 | clinicaltrials |
| NCT03668431 | Dabrafenib + Trametinib + PDR001 In Colorectal Cancer | unknown | Phase 2 | 25 | Massachusetts General HospitalOTHER | 1 | Jun 27, 2022 | clinicaltrials |
| NCT05019794 | Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations(FGFR) | unknown | Phase 2 | 80 | LianBio LLCINDUSTRY | 1 | Jun 27, 2022 | clinicaltrials |
| NCT05424432 | Short Course Neoadjuvant Chemo-radiotherapy Plus Toripalimab for Locally Advanced Resectble Squamous Cell Carcinoma of Esophagus(SCALE-2) | unknown | Phase 2 | 63 | Jiangsu Cancer Institute & HospitalOTHER | 1 | Jun 27, 2022 | clinicaltrials |
| NCT05410847 | Nab-paclitaxel Plus Camrelizumab and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells | unknown | Phase 2 | 30 | Hebei Medical UniversityOTHER | 0 | Jun 24, 2022 | clinicaltrials |
| NCT04418739 | Intravenous Human Albumin In Improving Pancreaticoduodenectomy Outcomes | unknown | Phase 2 | 122 | Universiti Kebangsaan Malaysia Medical CentreOTHER | 1 | Jun 16, 2022 | clinicaltrials |
| NCT02588781 | Pemetrexed Alone as Salvage Treatment in Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy: A Phase II Single Arm Prospective Study | unknown | Phase 2 | 23 | Samsung Medical CenterOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT05213312 | Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC | unknown | Phase 2 / Phase 3 | 90 | Shanghai Zhongshan HospitalOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT04215471 | NeoAdjuvant Therapy With Immunoreagent (SHR-1316) for Resectable Oesophageal Squamous Cell carciNoma(NATION1907II) | unknown | Phase 2 | 30 | Shanghai Zhongshan HospitalOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT05417230 | RC48-ADC Combinatioed Envolizumab in Locally Advanced or Metastatic Biliary Tract Cancer With Positive HER-2 | unknown | Phase 2 | 29 | Jiangsu Cancer Institute & HospitalOTHER | 0 | Jun 14, 2022 | clinicaltrials |
| NCT03947775 | HPV-SAVE_Merck_Sub-Study for Preventing Recurrence of HSIL | unknown | Phase 2 | 228 | University Health Network, TorontoOTHER | 1 | Jun 13, 2022 | clinicaltrials |
| NCT04174781 | Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCC | unknown | Phase 2 | 61 | Zhejiang UniversityOTHER | 1 | Jun 9, 2022 | clinicaltrials |
| NCT05409417 | Exploratory Study on Combined Conversion Immunotherapy for Liver Metastasis of MSS Type Initial Unresectable Colorectal Cancer Based on Gene Status | unknown | Phase 2 / Phase 3 | 40 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jun 8, 2022 | clinicaltrials |
| NCT03623737 | Comparing Paclitaxel/Cisplatin and Cisplatin/5-fluorouracil in Neo-CRT for ESCC | unknown | Phase 2 / Phase 3 | 248 | National Taiwan University HospitalOTHER | 1 | Jun 7, 2022 | clinicaltrials |
| NCT05406206 | Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line Therapy | unknown | Phase 2 | 27 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jun 6, 2022 | clinicaltrials |
| NCT03898895 | COmbination of Radiotherapy With Anti-PD-1 Antibody for unREseCtable Biliary Tract Cancer(CORRECT) | unknown | Phase 2 | 36 | Sun Yat-sen UniversityOTHER | 1 | Jun 2, 2022 | clinicaltrials |
| NCT05395780 | A Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Gastric Cancer or Gastroesophageal Junction Cancer | unknown | Phase 2 | 30 | Maxinovel Pty., Ltd.INDUSTRY | 1 | Jun 2, 2022 | clinicaltrials |
| NCT05402124 | The Colorectal Cancer Chemoprevention Acceleration and Improvement Platform (CRC-CHAMP) Study | unknown | Phase 2 | 100 | University of CalgaryOTHER | 1 | Jun 2, 2022 | clinicaltrials |
| NCT05399394 | Induction FOLFIRINOX Followed by Chemoradiation in Locally Advanced Pancreatic Cancer(FOLRT) | unknown | Phase 2 | 50 | Campus Bio-Medico UniversityOTHER | 0 | Jun 1, 2022 | clinicaltrials |
| NCT05396937 | Efficacy and Safety of T+A+RAD in HCC | unknown | Phase 2 | 42 | Fudan UniversityOTHER | 1 | May 31, 2022 | clinicaltrials |
| NCT05394415 | Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC(LATE) | unknown | Phase 1 / Phase 2 | 30 | Jiangsu Cancer Institute & HospitalOTHER | 1 | May 27, 2022 | clinicaltrials |
| NCT05346874 | Neoadjuvant TACiE in Locally Advanced Gastric Cancer | unknown | Phase 2 | 37 | Shanghai Zhongshan HospitalOTHER | 1 | May 26, 2022 | clinicaltrials |
| NCT02839343 | Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer | unknown | Phase 2 | 126 | Alliance for Clinical Trials in OncologyOTHER | 2 | May 24, 2022 | clinicaltrials |
| NCT05361161 | Transarterial Chemoembolization With Lipiodol in the Treatment of Initial Unresectable Gastric Cancer (GC) | unknown | Phase 2 | 60 | Gang WuOTHER | 0 | May 24, 2022 | clinicaltrials |
| NCT05381636 | Esophageal Arterial Infusion Chemotherapy Versus Systemic Intravenous Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Prospective, Multicentre, Randomised Controlled Clinical Study | unknown | Phase 2 | 120 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | May 19, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Aug 18, 2022source: clinicaltrials